NASDAQ: CRVO
Cervomed Inc Stock Forecast, Predictions & Price Target

Analyst price target for CRVO

Based on 6 analysts offering 12 month price targets for Cervomed Inc

Min Forecast
$10.00+13.64%
Avg Forecast
$20.33+131.06%
Max Forecast
$42.00+377.27%

Should I buy or sell CRVO stock?

Based on 6 analysts offering ratings for Cervomed Inc.

Strong Buy
Strong Buy
5 analysts 83.33%
Buy
1 analysts 16.67%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although CRVO's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates CRVO as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -8.02% per year. Learn More

Be the first to know when Wall Street analysts revise their CRVO stock forecasts and price targets.

CRVO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-03-26
lockedlocked$00.00+00.00%2025-03-18Find Out Why
lockedlocked$00.00+00.00%2025-03-18Find Out Why
lockedlocked$00.00+00.00%2025-03-18
lockedlocked$00.00+00.00%2025-03-13Find Out Why
HC Wainwright & Co.
Bottom 1%
1
BuyInitiates Coverage On$42.00+377.27%2024-12-05

1 of 1

Forecast return on equity

Is CRVO forecast to generate an efficient return?

Company
N/A
Industry
145.91%
Market
81.63%

Forecast return on assets

Is CRVO forecast to generate an efficient return on assets?

Company
N/A
Industry
35.93%

CRVO earnings per share forecast

What is CRVO's earnings per share in the next 2 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$2.17
Avg 2 year Forecast
-$2.76

CRVO revenue forecast

What is CRVO's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$2.8M-71.25%
Avg 2 year Forecast
$108.0M+1,009.06%
Avg 3 year Forecast
$303.0M+3,011.53%
CRVO's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CRVO revenue growth forecast

How is CRVO forecast to perform vs Biotechnology companies and vs the US market?

Company
208.59%
Industry
64.11%
Market
10.33%
CRVO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CRVO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CRVO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CRVO$8.80$20.33+131.06%Strong Buy
SAVA$1.59$2.00+25.79%Hold
TELO$2.60N/AN/A
VXRT$0.34$2.00+488.24%Strong Buy
ASMB$10.07$31.00+207.85%Strong Buy

Cervomed Stock Forecast FAQ

Is Cervomed Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: CRVO) stock is to Strong Buy CRVO stock.

Out of 6 analysts, 5 (83.33%) are recommending CRVO as a Strong Buy, 1 (16.67%) are recommending CRVO as a Buy, 0 (0%) are recommending CRVO as a Hold, 0 (0%) are recommending CRVO as a Sell, and 0 (0%) are recommending CRVO as a Strong Sell.

If you're new to stock investing, here's how to buy Cervomed stock.

What is CRVO's earnings growth forecast for 2025-2026?

(NASDAQ: CRVO) Cervomed's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.2%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.12%.

Cervomed's earnings in 2025 is -$16,290,695.On average, 4 Wall Street analysts forecast CRVO's earnings for 2025 to be -$18,863,143, with the lowest CRVO earnings forecast at -$23,323,287, and the highest CRVO earnings forecast at -$15,229,758.

In 2026, CRVO is forecast to generate -$24,019,504 in earnings, with the lowest earnings forecast at -$24,019,504 and the highest earnings forecast at -$24,019,504.

What is CRVO's revenue growth forecast for 2025-2031?

(NASDAQ: CRVO) Cervomed's forecast annual revenue growth rate of 208.59% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.11%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.33%.

Cervomed's revenue in 2025 is $9,737,974.On average, 3 Wall Street analysts forecast CRVO's revenue for 2025 to be $24,367,613, with the lowest CRVO revenue forecast at $17,405,438, and the highest CRVO revenue forecast at $35,681,148. On average, 1 Wall Street analysts forecast CRVO's revenue for 2030 to be $939,893,652, with the lowest CRVO revenue forecast at $939,893,652, and the highest CRVO revenue forecast at $939,893,652.

In 2031, CRVO is forecast to generate $2,636,923,857 in revenue, with the lowest revenue forecast at $2,636,923,857 and the highest revenue forecast at $2,636,923,857.

What is CRVO's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: CRVO) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 35.93%.

What is CRVO's Price Target?

According to 6 Wall Street analysts that have issued a 1 year CRVO price target, the average CRVO price target is $20.33, with the highest CRVO stock price forecast at $42.00 and the lowest CRVO stock price forecast at $10.00.

On average, Wall Street analysts predict that Cervomed's share price could reach $20.33 by Mar 26, 2026. The average Cervomed stock price prediction forecasts a potential upside of 131.06% from the current CRVO share price of $8.80.

What is CRVO's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: CRVO) Cervomed's current Earnings Per Share (EPS) is -$2.02. On average, analysts forecast that CRVO's EPS will be -$2.17 for 2025, with the lowest EPS forecast at -$2.68, and the highest EPS forecast at -$1.75. In 2026, CRVO's EPS is forecast to hit -$2.76 (min: -$2.76, max: -$2.76).

What is CRVO's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: CRVO) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.